While many other clinical and animal model studies have demonstrated decreased fibrosis after angiotensin II blockade [23, 24, 26–28], oral administration of clinical doses for common indications of hypertension, coronary artery disease, congestive heart failure, or diabetes did not show an effect on range of motion after total knee arthroplasty in our study population. This evidence concerns the gene AGT and coronary artery disorder.